Showing 7021-7030 of 8826 results for "".
- Review: Dermoscopic Patterns May Improve Differentiation of Acral Melanoma and Nevihttps://practicaldermatology.com/news/review-dermoscopic-patterns-may-improve-differentiation-of-acral-melanoma-and-nevi/2486062/A systematic review and meta-analysis in JAMA Dermatology provides updated evidence on dermoscopic features that differentiate acral lentiginous melanoma (ALM) from benign acral nevi. Investigators searched Embase, P
- INTEGUMENT-OLE Data Show Sustained Efficacy of Roflumilast in Early Childhood ADhttps://practicaldermatology.com/news/integument-ole-data-show-sustained-efficacy-of-roflumilast-in-early-childhood-ad/2486045/The 56-week phase 3 open-label extension for the INTEGUMENT trial (INTEGUMETN-OLE) indicated once-daily roflumilast cream 0.05% maintained efficacy and demonstrated favorable long-term safety in children aged 2 to 5 years with mild-to-moderate atopic dermatitis (AD
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- BE BOLD: Bimekizumab Shows Superiority Over IL-23 Inhibitor in Psoriatic Arthritishttps://practicaldermatology.com/news/be-bold-trial-bimekizumab-shows-superiority-over-il-23-inhibitor-in-psoriatic-arthritis/2486038/Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity at Week 16 in adults with active psoriatic arthritis (PsA), according to topline results from the phase 3 BE BOLD head-to-head trial announced by UCB.
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.
- Upadacitinib Shows Rapid, Durable Skin Pain Relief in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-rapid-durable-skin-pain-relief-in-moderate-to-severe-atopic-dermatitis/2485627/Poster data presented at Winter Clinical Hawaii indicated rapid and sustained reductions in skin pain among adults and adolescents with moderate-to-severe atopic dermatitis (AD) treated with upadacitinib. The analysis emphasized skin pain as a clinically meaningful
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://practicaldermatology.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Staphylococcus aureus Implicated as Central Driver of Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/staphylococcus-aureus-implicated-as-central-driver-of-pediatric-atopic-dermatitis/2485614/A comprehensive literature analysis presented at the South Beach Symposium identified Staphylococcus aureus as a key contributor to pediatric atopic dermatitis (AD) pathogenesis, extending beyond disease exacerbation to underlying inflammation and prurit
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://practicaldermatology.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April
- AbbVie Files FDA, EMA Applications for Upadacitinib in Non-Segmental Vitiligohttps://practicaldermatology.com/news/abbvie-files-fda-ema-applications-for-upadacitinib-in-non-segmental-vitiligo/2485564/AbbVie has submitted regulatory applications to the US Food and Drug Administration and European Medicines Agency seeking approval of upadacitinib (RINVOQ) for the treatment of adults and adolescents with non-segmental vitiligo (NSV), according to a